Isotechnika Pharma (AUPH) Earns News Sentiment Rating of 0.11
Media headlines about Isotechnika Pharma (NASDAQ:AUPH) (TSE:AUP) have been trending somewhat positive on Saturday, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Isotechnika Pharma earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.7390379321858 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:
- Isotechnika Pharma Inc. (AUPH) Expected to Post Earnings of -$0.17 Per Share (americanbankingnews.com)
- Financial Comparison: Trillium Therapeutics (TRIL) vs. Isotechnika Pharma (AUPH) (americanbankingnews.com)
- Don't Get Greedy With Aurinia Pharmaceuticals Stock (finance.yahoo.com)
- Isotechnika Pharma Inc. (AUPH) Given Consensus Recommendation of “Buy” by Analysts (americanbankingnews.com)
AUPH stock opened at $5.35 on Friday. The stock has a market cap of $452.20, a price-to-earnings ratio of -5.82 and a beta of 2.26. Isotechnika Pharma has a one year low of $4.41 and a one year high of $8.19.
AUPH has been the subject of a number of research reports. Seaport Global Securities reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Isotechnika Pharma in a research note on Friday, March 16th. ValuEngine raised shares of Isotechnika Pharma from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. BidaskClub raised shares of Isotechnika Pharma from a “sell” rating to a “hold” rating in a research note on Thursday, January 25th. Zacks Investment Research raised shares of Isotechnika Pharma from a “strong sell” rating to a “hold” rating in a research note on Monday, January 22nd. Finally, Royal Bank of Canada assumed coverage on shares of Isotechnika Pharma in a research report on Thursday, February 8th. They set an “outperform” rating and a $9.00 price target for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Isotechnika Pharma currently has an average rating of “Buy” and an average target price of $10.92.
Isotechnika Pharma Company Profile
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has partnership agreements with Paladin Labs Inc and 3SBio, Inc The company was formerly known as Isotechnika Pharma Inc and changed its name to Aurinia Pharmaceuticals Inc in October 2013.
Receive News & Ratings for Isotechnika Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isotechnika Pharma and related companies with MarketBeat.com's FREE daily email newsletter.